Alpha DaRT alpha-particle therapy, key 2026 trial catalysts, cash/dilution risks, and M&A takeover potential. See more.
HekaBio K.K., (Headquarters: Chuo-ku, Tokyo) announces that the innovative solid tumor treatment device 'Alpha DaRT (Diffusing Alpha Radiation Therapy),' developed by Alpha Tau Medical Ltd.
– Aiming to establish af-001 as a new therapeutic option for radioactive iodine (RAI)-naïve patients with differentiated thyroid cancer – This clinical trial is designed based on the results of an ...
Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from ...
New Technique to Fight Prostate Cancer: IAEA organizes first-of-a-kind training for Radiopharmacists
For the first time, radiopharmacists from across Central and Eastern Europe learned about an emerging technique in treating prostate cancer at an IAEA course organized at the National Centre for ...
Mr. Levy will be available for 1x1 investor meetings at the conference. Please reach out to your Sidoti representative to schedule. About Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an ...
Mr. Levy will be available for 1x1 investor meetings. Please reach out to your Jefferies representative to schedule. About Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results